• Thu, May 11, 2023
Matthew Barcus Reiterated (XLO) at Strong Buy and Held Target at $7 on, May 11th, 2023
Matthew Barcus of Chardan Capital, Reiterated "Xilio Therapeutics, Inc." (XLO) at Strong Buy and Held Target at $7 on, May 11th, 2023.
Matthew has made no other calls on XLO in the last 4 months.
There is 1 other peer that has a rating on XLO. Out of the 1 peers that are also analyzing XLO, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Michael Ulz of "Morgan Stanley" Maintained at Buy with Decreased Target to $10 on, Friday, January 27th, 2023
Like: 👍
